NCT04794296 Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
| NCT ID | NCT04794296 |
| Status | Recruiting |
| Phase | — |
| Sponsor | French Africa Pediatric Oncology Group |
| Condition | Childhood ALL |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2021-11-15 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2021-11-15 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.
Eligibility Criteria
Inclusion Criteria: Children 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2 \- Exclusion Criteria: ALL L3 (Burkitt) ALL previously treated with chemotherapy Trisomy 21
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04794296 clinical trial?
This trial is open to participants of all sexes, up to 18 Years, studying Childhood ALL. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04794296 currently recruiting?
Yes, NCT04794296 is actively recruiting participants. Contact the research team at ndella.diouf@gfaop.org for enrollment information.
Where is the NCT04794296 trial being conducted?
This trial is being conducted at Abidjan, Côte d’Ivoire, Conakry, Guinea, Dakar, Senegal.
Who is sponsoring the NCT04794296 clinical trial?
NCT04794296 is sponsored by French Africa Pediatric Oncology Group. The trial plans to enroll 500 participants.